Table 3.
Characteristics of T790M-negative patients (n = 25)
| Variables | Overall (n = 25) | |
|---|---|---|
| Age (years), mean (± SD) | 67.7 (±12.6) | |
| Sex, n (%) | Male | 16 (64.0) |
| Female | 9 (36.0) | |
| Smoking status, n (%) | Smoker | 17 (68.0) |
| Non-smoker | 8 (32.0) | |
| Histology, n (%) | Adenocarcinoma | 25 (100) |
| ECOG-PS, n (%) | 0 | 12 (48.0) |
| 1 | 10 (40.0) | |
| 2 | 3 (12.0) | |
| 3 | 0 (0.0) | |
| 4 | 0 (0.0) | |
| Clinical stage, n (%) | III | 5 (20.0) |
| IV | 20 (80.0) | |
| Metastases, n (%) | Liver | 0 (0.0) |
| Bone | 7 (28.0) | |
| Brain | 9 (36.0) | |
| EGFR mutation type, n (%) | 19 del | 10 (40.0) |
| L858R | 11 (44.0) | |
| Othersa | 4 (16.0) | |
| Treatment before T790M test, n (%) | G1,2 EGFR-TKI | 25 (100) |
| Treatment after T790M test, n (%) | Chemotherapy | 14 (56.0) |
| G1,2 EGFR-TKI | 6 (24.0) | |
| Osimertinib | 7 (28.0) | |
| ICI or Chemo + ICI | 9 (36.0) |
ECOG-PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; 19 del, exon 19 deletion; TKI, tyrosine kinase inhibitor; ICI, immune checkpoint inhibitors
aG719A, G719C, G719S, G719X, L861Q, and exon 20 insertions